This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Endo And Metamark Announce Sale Of HealthTronics Laboratory Solutions

Stocks in this article: ENDP

MALVERN, Pa. and CAMBRIDGE, Mass., Aug. 12, 2013 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) today announced that its wholly owned subsidiary, HealthTronics, Inc. has entered into a definitive agreement to sell its anatomical pathology business, HealthTronics Laboratory Solutions, Inc., ("HLS") to Metamark Genetics, Inc. ("Metamark") for an undisclosed amount.   As previously announced Endo Health Solutions is pursuing strategic alternatives for HealthTronics, Inc. and believes the sale of HLS creates progress in this process.  

Metamark is at the leading edge of research in cancer prognosis, which is a critical tool in determining appropriate cancer therapy. In the age of personalized medicine, particularly in oncology, Metamark's proprietary multiplex proteomic platform has the potential to reshape the landscape in cancer diagnosis and therapy.

HLS provides anatomical pathology services primarily to the urology community. The HLS pathology labs are located in Georgia and Pennsylvania and provide laboratory and diagnostic services to urologists throughout the U.S., with client practices in 41 states.  In addition, HLS manages pathology laboratories for physician practice groups, provides administrative services to in-office pathology labs for practice groups, and provides pathology services to physicians.

"HLS is a recognized national reference lab providing specialized pathology services to the urology community with a reputation for quality," said Shawn M. Marcell, president and CEO of Metamark Genetics. "We believe joining forces with HLS will be instrumental to our success as we commercialize ProMark™, Metamark's novel prostate cancer test."

Kelly Huang, PhD, President of HealthTronics, stated "Metamark has strong ambitions for growth, shares our commitment to improved patient outcomes, and is dedicated to continue to serve the needs of urologists and the patients for which they care."

About HealthTronics

HealthTronics has been a national provider of urological and interventional oncology services and products for more than 20 years. Headquartered in Austin, Texas, with anatomical pathology laboratories in three states, the company provides the most advanced technology and premiere support systems to urologists, interventional radiologists, hospitals, surgery centers and clinics across the United States. HealthTronics is an operating company of Endo Health Solutions Inc.

About Endo

Endo Health Solutions Inc. (Endo) is a U.S.-based specialty healthcare company with four distinct business segments that are focused on branded and generic pharmaceuticals, devices and services, each providing quality products to our customers while improving the lives of patients.  Through our operating companies – AMS, Endo Pharmaceuticals, HealthTronics and Qualitest – Endo is dedicated to finding solutions for the unmet needs of patients. Learn more at www.endo.com.

About Metamark

Metamark Genetics, Inc. ("Metamark") is a privately held biotechnology company founded in 2007 to develop new function-based prognostic and diagnostic tests aimed at improving cancer care.  The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon and breast cancers. During 2013, Metamark plans to commercialize ProMark – its lead prostate cancer prognostic test – through its Cambridge, MA CLIA-certified laboratory.  For more information, please visit the company's Website at www.metamarkgenetics.com.  Metamark™ and ProMark™ are trademarks of Metamark Genetics, Inc.

SOURCE Endo Health Solutions

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs